First-in-human studies of seletalisib, an orally bioavailable small-molecule PI3Kδ inhibitor for the treatment of immune and inflammatory diseases

Eric Helmer, Mark Watling,Emma Jones,Dominique Tytgat, Mark Jones,Rodger Allen,Andrew Payne,Annelize Koch,Eugene Healy

European Journal of Clinical Pharmacology（2017）

引用 20|浏览6

暂无评分

摘要

PI3Ks are potential therapeutic targets in immune-inflammatory diseases. These studies aimed to investigate the safety, tolerability and PK profile of seletalisib, a selective inhibitor of PI3Kδ in humans.

查看译文

关键词

Inflammatory,PI3Kδ,Phase I,Pharmacodynamic,Pharmacokinetic,Seletalisib

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要